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Alpha-one antitrypsin (AAT) deficiency is a genetic disease that results in both lung disease and 
potentially liver failure in affected patients. In un-affected people AAT is produced in the liver 
and secreted to act as an anti-protease (primarily counteracting the effects of neutrophil 
elastase) in the lung. On-going human clinical trials have focused on intra-muscular delivery of 
adeno-associated virus (AAV1) to patients. The goal of delivery to the muscle is to have the 
myocytes serve as bio-factories to produce normal AAT protein and secrete it into the blood 
where it can exert its normal function in the lung. In the last Phase II trial patients in the highest 
dose cohort were given 100 intra-muscular (IM) injections with serum AAT levels still below 
therapeutic thresholds.  
Previous work has shown that delivering AAV vector to the musculature of the limb via the 
vasculature, while blood flow is obstructed using a tourniquet, leads to wide-spread gene 
expression in myocytes. We hypothesize that local delivery via IM injection results in saturated 
AAT expression within the myocytes surrounding the injection sight and that a more widespread 
delivery would result in an overall increase in serum AAT levels with the same dose of AAV 
gene therapy vector due to production by a larger overall number of myocytes. We have been 
able to show that we can attain similar or slightly higher (573.0 ng/ml versus 562.5 ng/nl) serum 
AAT levels using a vascular delivery method in rhesus macaques when compared to IM 
delivery. These results have been obtained using AAV1. Animals receiving either AAV1 or 
AAV8 show a decrease in muscle immune cell infiltrates following intra-vascular delivery versus 
IM delivery, which may improve long-term expression. Serum AAT data from animals dosed 
using AAV8, a serotype shown to better target muscle following vascular delivery, are currently 
being processed.  
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